116 related articles for article (PubMed ID: 32659024)
21. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
22. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis.
Liauw SL; Ham SA; Das LC; Rudra S; Packiam VT; Koshy M; Weichselbaum RR; Becker YT; Bodzin AS; Eggener SE
J Natl Cancer Inst; 2020 Aug; 112(8):847-854. PubMed ID: 31728517
[TBL] [Abstract][Full Text] [Related]
23. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
24. Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance.
Courtney PT; Deka R; Kotha NV; Cherry DR; Salans MA; Nelson TJ; Kumar A; Luterstein E; Yip AT; Nalawade V; Parsons JK; Kader AK; Stewart TF; Rose BS
J Natl Compr Canc Netw; 2022 Feb; 20(2):151-159. PubMed ID: 35130495
[TBL] [Abstract][Full Text] [Related]
25. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
26. Recreational Physical Activity in Relation to Prostate Cancer-specific Mortality Among Men with Nonmetastatic Prostate Cancer.
Wang Y; Jacobs EJ; Gapstur SM; Maliniak ML; Gansler T; McCullough ML; Stevens VL; Patel AV
Eur Urol; 2017 Dec; 72(6):931-939. PubMed ID: 28711382
[TBL] [Abstract][Full Text] [Related]
27. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.
Shen X; Keith SW; Mishra MV; Dicker AP; Showalter TN
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1154-9. PubMed ID: 22270175
[TBL] [Abstract][Full Text] [Related]
28. Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.
Yang DD; Muralidhar V; Mahal BA; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Martin NE; King MT; Mouw KW; Choueiri TK; Trinh QD; Nguyen PL; Orio PF
Urol Oncol; 2020 Sep; 38(9):735.e9-735.e15. PubMed ID: 32654951
[TBL] [Abstract][Full Text] [Related]
29. Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data.
He J; Albertsen PC; Moore D; Rotter D; Demissie K; Lu-Yao G
Eur Urol; 2017 May; 71(5):760-763. PubMed ID: 27939073
[TBL] [Abstract][Full Text] [Related]
30. 10-Year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specific Antigen Screening Era.
Mendhiratta N; Lee T; Prabhu V; Llukani E; Lepor H
Urology; 2015 Oct; 86(4):783-8. PubMed ID: 26163812
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease?
Kim MM; Hoffman KE; Levy LB; Frank SJ; Pugh TJ; Choi S; Nguyen QN; McGuire SE; Lee AK; Kuban DA
Eur J Cancer; 2012 Jul; 48(11):1664-71. PubMed ID: 22336663
[TBL] [Abstract][Full Text] [Related]
32. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
J Clin Oncol; 2003 Jun; 21(11):2163-72. PubMed ID: 12775742
[TBL] [Abstract][Full Text] [Related]
33. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
34. The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml.
Pashtan I; Chen MH; D'Amico AV
Cancer Epidemiol; 2014 Oct; 38(5):613-8. PubMed ID: 25164550
[TBL] [Abstract][Full Text] [Related]
35. Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.
Tilki D; Chen MH; Wu J; Huland H; Graefen M; Braccioforte M; Moran BJ; D'Amico AV
JAMA Oncol; 2019 Feb; 5(2):213-220. PubMed ID: 30452521
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Social Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients: A Systematic Review and Meta-analysis.
Vince RA; Jiang R; Bank M; Quarles J; Patel M; Sun Y; Hartman H; Zaorsky NG; Jia A; Shoag J; Dess RT; Mahal BA; Stensland K; Eyrich NW; Seymore M; Takele R; Morgan TM; Schipper M; Spratt DE
JAMA Netw Open; 2023 Jan; 6(1):e2250416. PubMed ID: 36630135
[TBL] [Abstract][Full Text] [Related]
37. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):147-52. PubMed ID: 19744800
[TBL] [Abstract][Full Text] [Related]
38. Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database.
Zumsteg ZS; Chen Z; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Spratt DE; Sandler HM; Freedland SJ
Prostate; 2017 Feb; 77(2):154-163. PubMed ID: 27683213
[TBL] [Abstract][Full Text] [Related]
39. Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database.
Roy S; Morgan SC
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):630-636. PubMed ID: 31130340
[TBL] [Abstract][Full Text] [Related]
40. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act.
Mahal BA; Aizer AA; Ziehr DR; Hyatt AS; Lago-Hernandez C; Chen YW; Choueiri TK; Hu JC; Sweeney CJ; Beard CJ; D'Amico AV; Martin NE; Trinh QD; Nguyen PL
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):273-9. PubMed ID: 24980272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
